New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:08 EDTCLSNCelsion's ThermoDox for liver cancer shows positive overall survival data
Celsion updated results from its retrospective analysis of the company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation in primary liver cancer. As of June 30, the latest quarterly Overall Survival analysis demonstrated that in 41% of the study patients, the combination of ThermoDox and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. Data from the latest HEAT Study post-hoc analysis continued to strongly suggest that ThermoDox may significantly improve OS compared to a RFA control in patients whose lesions undergo RFA treatment for 45 minutes or more.
News For CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTCLSNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTCLSNCelsion initiated with a Buy at Cantor
Subscribe for More Information
October 29, 2014
08:18 EDTCLSNCelsion presents positive data for its Therasilence platform
Celsion presented data related to TheraSilence, its lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2, Celsion's RNA interference therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June. Intravenous delivery of RNA inhibiting VEGFR-2, a tumor angiogenesis factor, with the TheraSilence delivery system resulted in significant knockdown of VEGFR-2 transcript in lungs, reduction in tumor blood vessel density and inhibition of tumor growth. Systemically administered RNA complexes using the TheraSilence delivery system demonstrated a good tolerability profile.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use